TLDR
- Cathie Wood’s ARK funds purchased 97,783 DraftKings shares for $3.05 million across three ETFs on October 29
- Pacific Biosciences received $2.03 million investment with ARK buying over 1 million shares
- 10X Genomics saw $2.96 million in purchases split between ARKK and ARKG funds
- ARK divested $650,161 worth of Shopify stock ahead of November 4 earnings report
- Sports betting stock DraftKings trading 18% lower in 2025 when ARK made purchase
ARK Investment Management disclosed its October 29, 2025 trading activity, showing purchases totaling over $8 million across sports betting and biotechnology sectors. Cathie Wood’s firm bought 97,783 shares of DraftKings valued at $3,046,918 through its ARKK, ARKW, and ARKF funds.
The sports betting platform’s shares have declined 18% year-to-date. Over the five trading days before ARK’s purchase, DraftKings stock dropped 11.1%.
Competition in the sports betting market increased after Polymarket announced plans to launch U.S. operations. The prediction market platform will focus on sports betting when it returns to the American market in the coming weeks.
DraftKings purchased Railbird Technologies recently to enter the prediction market space. This acquisition marks the company’s expansion beyond traditional sports wagering products.
ARK Accumulates Biotech Stocks
Wood’s funds made substantial investments in genomics companies during Wednesday’s trading. The ARKK fund bought 1,028,318 Pacific Biosciences shares worth $2,025,786.
Pacific Biosciences creates advanced DNA sequencing technology and systems. ARK has maintained a consistent buying pattern for this stock throughout the past week.
ARK purchased 221,801 shares of 10X Genomics for $2,958,825 across two funds. The ARKK and ARKG ETFs split this investment.
10X Genomics manufactures instruments and software for cellular analysis research. The company has seen continued accumulation from ARK over multiple trading sessions.
Both biotech companies will announce quarterly financial results next week. ARK’s buying activity ahead of these earnings may signal positive expectations.
Shopify Holdings Trimmed
The ARKF fund sold 3,633 Shopify shares totaling $650,161 on October 29. This continues ARK’s recent pattern of reducing exposure to the e-commerce platform.
Shopify’s third quarter fiscal 2025 earnings are scheduled for November 4. ARK has been decreasing its position in the Canadian company ahead of this report.
Wood has been reallocating capital away from traditional e-commerce stocks. The firm is increasing investments in artificial intelligence, genomics, and next-generation technology sectors instead.
Investment Philosophy on Display
ARK’s October 29 trades demonstrate the firm’s focus on disruptive technology sectors. The combined biotech purchases exceeded $5 million, showing strong conviction in genomics.
The DraftKings investment represents ARK’s willingness to buy during price weakness. Wood has historically made large purchases when she identifies long-term value despite short-term declines.
ARK Investment Management publishes daily trade reports through fund disclosures. These reports provide transparency into the firm’s portfolio management decisions and sector preferences.
The three largest purchases on Wednesday totaled more than $8 million. Each investment targets industries that ARK considers high-growth innovation opportunities.
Wood’s strategy centers on identifying companies with disruptive potential in emerging markets. The genomics sector has been a consistent focus area for ARK’s ARKG fund since its inception.
The firm’s October 29 activity shows continued confidence in biotech innovation. Pacific Biosciences and 10X Genomics represent ARK’s thesis on the future of genetic research and medical technology.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
